Clozapine inhibits catalepsy induced by olanzapine and loxapine, but prolongs catalepsy induced by SCH 23390 in rats

被引:25
作者
Kalkman, HO
Neumann, V
Tricklebank, MD
机构
[1] Preclin. Research Sandoz Pharma Ltd., Building 360-405
关键词
clozapine; olanzapine; loxapine; SCH; 23390; catalepsy;
D O I
10.1007/PL00004955
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Loxapine (0.3 mg/kg s.c.), olanzapine (10 mg/kg s.c.) and SCH 23390 (R-(+)-chloro-2, 3, 4, 5-tetrahydro-3-methyl-5-phenyl- 1-H-3-benzazepine; 1 mg/kg, s.c.), but not clozapine (10 mg/kg, s.c.), induced catalepsy in rats. Co-administration of clozapine (1, 3 and 10 mg/kg s.c.) dose-dependently inhibited loxapine-induced catalepsy. Clozapine (10 mg/kg s.c.) also prevented the induction of catalepsy by olanzapine. In addition, clozapine abolished the catalepsy induced by loxapine when it was administered after the response had fully developed. In contrast, the duration of SCH 23390-induced catalepsy was prolonged by clozapine, indicating that its anti-catalepsy effects against olanzapine and loxapine are unlikely to be caused by muscle relaxation, sedation or stimulation. Since SCH 23390-induced catalepsy is reported to be blocked by scopolamine, dizocilpine (MK-801) or 8-hydroxy-dipropylamino-tetralin, it is unlikely that muscarinic blockade, NMDA ion channel blockade and 5-HT1A receptor agonism, respectively, are involved in clozapine's action, but the mechanism by which clozapine exerts this anti-cataleptic effect remains unknown.
引用
收藏
页码:361 / 364
页数:4
相关论文
共 25 条
[1]  
ANDERSON JJ, 1995, J PHARMACOL EXP THER, V274, P928
[2]   TISSUE CONCENTRATIONS OF CLOZAPINE AND ITS METABOLITES IN THE RAT [J].
BALDESSARINI, RJ ;
CENTORRINO, F ;
FLOOD, JG ;
VOLPICELLI, SA ;
HUSTONLYONS, D ;
COHEN, BM .
NEUROPSYCHOPHARMACOLOGY, 1993, 9 (02) :117-124
[3]   DOPAMINE AND THE PATHO-PHYSIOLOGY OF DYSKINESIAS INDUCED BY ANTIPSYCHOTIC-DRUGS [J].
BALDESSARINI, RJ .
ANNUAL REVIEW OF NEUROSCIENCE, 1980, 3 :23-41
[4]   Radioreceptor binding profile of the atypical antipsychotic olanzapine [J].
Bymaster, FP ;
Calligaro, DO ;
Falcone, JF ;
Marsh, RD ;
Moore, NA ;
Tye, NC ;
Seeman, P ;
Wong, DT .
NEUROPSYCHOPHARMACOLOGY, 1996, 14 (02) :87-96
[5]  
CASEY DE, 1989, PSYCHOPHARMACOLOGY, V99, P47
[6]  
CLAGHORN J, 1987, J CLIN PSYCHOPHARM, V7, P377
[7]  
EREVALO GJG, 1993, MOV DISORD, V8, P349
[8]  
FISCHER-CORNELSSEN K A, 1976, Psychopharmacology Bulletin, V12, P34
[9]   CATALEPSY AS A RODENT MODEL FOR DETECTING ANTIPSYCHOTIC-DRUGS WITH EXTRAPYRAMIDAL SIDE-EFFECT LIABILITY [J].
HOFFMAN, DC ;
DONOVAN, H .
PSYCHOPHARMACOLOGY, 1995, 120 (02) :128-133
[10]  
IORIO LC, 1983, J PHARMACOL EXP THER, V226, P462